+31.6%
AMT vs MRNA
+554.4%
-522.8%
-45.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.8% | +5.4% | -2.6% | +2.7% |
| 7D | +1.1% | -1.1% | +2.2% | +1.2% |
| 30D | +4.4% | +126.1% | -121.8% | +0.2% |
| 3M | -5.2% | +190.0% | -195.2% | -10.1% |
| 6M | -0.8% | +157.2% | -158.1% | -5.6% |
| YTD | +3.3% | +388.2% | -384.9% | -4.7% |
| 1Y | -6.0% | +467.0% | -473.1% | -14.0% |
| 3Y | +9.6% | +36.1% | -26.5% | +5.0% |
| 5Y | -29.2% | -68.0% | +38.7% | -30.3% |
| All | +31.6% | +554.4% | -522.8% | +20.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling